ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose
Pharmaceutical Technology
At ACC 2026, the phase II CADENCE trial reported results for sotatercept (WINREVAIR) in adults with combined post- and precapillary pulmonary hypertension associated with HFpEF.
pharminent
April 1, 2026 (Last updated: April 1, 2026)
Pharmaceutical Technology
At ACC 2026, the phase II CADENCE trial reported results for sotatercept (WINREVAIR) in adults with combined post- and precapillary pulmonary hypertension associated with HFpEF.
